{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-000449","form_type":"8-K","ticker":"SPRB","cik":"0001683553","company_name":"SPRUCE BIOSCIENCES, INC.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.132665+00:00","generated_at":"2026-06-20T17:58:35.794641+00:00","sec_items":["1.01","2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Spruce Biosciences licenses tildacerfont to Kaken for Japan; $15M upfront, up to $65M milestones","bullets":["Exclusive Japan rights for tildacerfont in CAH; $15M upfront, up to ~$65M in development/regulatory/commercial milestones.","Preliminary cash, cash equivalents and investments as of Dec 31, 2022: approximately $79M (unaudited).","Pediatric CAH trial amended: study length increased to 12 weeks plus 2-year open-label extension; age lowered to 2 years.","Additional data to be collected: PK at 50mg and 200mg doses, A4 reduction, GC reduction, and 12-week safety data."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-000449","json":"https://secwatch.observer/filing/0000950170-23-000449.json","markdown":"https://secwatch.observer/filing/0000950170-23-000449.md","text":"https://secwatch.observer/filing/0000950170-23-000449.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1683553/000095017023000449/0000950170-23-000449-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1683553/000095017023000449/sprb-20230105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:58:35.794641+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6910b6d23c4e136e3708a2982158afc888e0963a","claim":"SPRUCE BIOSCIENCES, INC. entered into Collaboration and License Agreement with Kaken Pharmaceutical Co., LTD. valued at $15.0 million (effective 2023-01-05).","evidence_excerpt":"On January 5, 2023, Spruce Biosciences, Inc. (the “Company”) entered into a Collaboration and License Agreement (the “Agreement”) with Kaken Pharmaceutical Co., LTD. (“Kaken”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1683553/000095017023000449/0000950170-23-000449-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Kaken Pharmaceutical Co., LTD."},{"label":"Value","value":"$15.0 million"},{"label":"Effective","value":"2023-01-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}